General Information of This Antibody
Antibody ID
ANI0KWFEQ
Antibody Name
AXL-183-N52Q
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Humanized IgG1-kappa
Antigen Name
Tyrosine-protein kinase receptor UFO (AXL)
 Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AXL-183-N52Q-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 24.70% (Day 18) Positive AXL expression (AXL+++/++)
Method Description
In the LCLC-103H xenograft model,therapeutic treatment with a single dose of 1 mg/kg in anti-tumor activity in the AXL-ADC panel.
In Vivo Model Lung cancer CDX model
In Vitro Model Lung large cell carcinoma LCLC-103H cells CVCL_1375
References
Ref 1 Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nat Med. 2018 Feb;24(2):203-212.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.